Tag Archives: Aranesp

FDA Approves Risk Management Plan for ESAs

Cancer patients will learn more from their doctors about the possible risks and benefits of erythropoiesis-stimulating agents (ESAs) to manage anemia during chemotherapy under a new program just approved by the FDA. ESAs can be given to chemotherapy patients to reduce the need for blood transfusions.  However, there can be problems with ESAs including causing some tumors to grow faster or some patients to die sooner.  They can also increase risk for blood clots, heart failure, heart attack or stroke. ESAs, including Procrit®, Epogen®, and Aranesp®, are now covered by a REMS or Risk Evaluation and Mitigation Strategy which requires that patient receive a Medication Guide from their health care

Amgen Changes Pricing Policy for Aranesp

As of October 1, 2008 Amgen will no longer offer rebates to oncologists and oncology clinics who purchase Aranesp® (darbepoetin alfa) although they will provide larger discounts at the time of purchase. They also will no longer base discounts for Neulasta® (pegfilgrastim) and Neupogen© (filgrastim) on purchases of Aranesp, a process known as bundling.  Neulasta and Neupogen help raise white cell counts lowered by chemotherapy and are designed to prevent infection resulting from treatment. Nancy Roach, Chairperson of the C3: Colorectal Cancer Coalition, told the New York Times, It’s a step in the right direction. In addition, she told C3 Research News that C3 supports fair pricing policies for drugs

Top